Prostate Cancer Drug
Dr. Howard Scher discusses MDV3100, a novel oral androgen receptor antagonist. The agent is under study for the treament of castrate-resistant prostate cancer. Patrice Wendling of the Global Medical News Network (GMNN) reports from the annual Genitourinary Cancers Symposium.
Tags: global medical news, Cancer, Drug, genitourinary cancers, receptor antagonist, Prostate
Related posts:
- Prostate Cancer Drug Improves Survival
- The National Foundation for Cancer Research and The Prostate Cancer Foundation Unite with Burnham Institute to Expedite Cancer Drug Discovery
- New Medical Breakthroughs Will Change the Way Prostate Disease is Treated
- Best Way to Get Prostate Cancer News About the Latest New Treatments
- NHS spend on testicular and prostate Cancer compared to Breast and cervical ?